STOK

8.33

4.69% -0.41

Dopo l'orario di chiusura: 8.40 0.07 +0.84%

Stoke Therapeutics Inc (STOK)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$8.74

Aprire:

$8.9

Volume 24 ore:

1.04M

Relative Volume:

1.44

Capitalizzazione di mercato:

$441.21M

Reddito:

$8.78M

Utile/perdita netta:

$-104.70M

Rapporto P/E:

-3.5148

EPS:

-2.37

Flusso di cassa netto:

$-82.68M

1 W Prestazione:

-22.00%

1M Prestazione:

-15.00%

6M Prestazione:

-43.72%

1 anno Prestazione:

+55.41%

Intervallo 1D:

$8.20

$9.14

Intervallo di 1 settimana:

$8.20

$11.11

Portata 52W:

$5.21

$17.58

Stoke Therapeutics Inc Stock (STOK) Company Profile

Nome

Stoke Therapeutics Inc

Settore

Healthcare (1169)

Industria

Biotechnology (678)

Telefono

781-430-8200

Indirizzo

45 WIGGINS AVENUE, BEDFORD, MA

Dipendente

110

Cinguettio

@stoketx

Prossima data di guadagno

2024-11-05

Ultimi documenti SEC

STOK's Discussions on Twitter

Confronta STOK con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
STOK Stoke Therapeutics Inc	8.33	441.21M	8.78M	-104.70M	-82.68M	-2.37
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-20	Iniziato	Chardan Capital Markets	Buy
2024-10-14	Ripresa	Leerink Partners	Outperform
2024-03-26	Aggiornamento	TD Cowen	Market Perform → Outperform
2023-11-20	Ripresa	JP Morgan	Neutral
2023-07-25	Downgrade	TD Cowen	Outperform → Market Perform
2023-05-01	Aggiornamento	BofA Securities	Underperform → Neutral
2023-04-26	Ripresa	Canaccord Genuity	Buy
2023-01-06	Downgrade	BofA Securities	Buy → Underperform
2022-10-24	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2022-01-31	Iniziato	Jefferies	Buy
2021-12-03	Iniziato	BofA Securities	Buy
2021-11-22	Aggiornamento	JP Morgan	Neutral → Overweight
2021-05-18	Iniziato	UBS	Neutral
2021-05-10	Aggiornamento	Wedbush	Neutral → Outperform
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-02-10	Downgrade	Wedbush	Outperform → Neutral
2020-12-15	Ripresa	H.C. Wainwright	Buy
2020-12-11	Reiterato	Needham	Buy
2020-10-23	Iniziato	Cantor Fitzgerald	Overweight
2020-09-29	Ripresa	JP Morgan	Neutral
2020-09-29	Iniziato	Needham	Buy
2019-12-18	Iniziato	Wedbush	Outperform
2019-11-12	Iniziato	BTIG Research	Buy
2019-10-25	Iniziato	H.C. Wainwright	Buy
2019-07-15	Iniziato	Canaccord Genuity	Buy
2019-07-15	Iniziato	Cowen	Outperform
2019-07-15	Iniziato	Credit Suisse	Outperform
2019-07-15	Iniziato	JP Morgan	Overweight

Mostra tutto

Stoke Therapeutics Inc Borsa (STOK) Ultime notizie

04:05 AM

Equities Analysts Offer Predictions for STOK Q1 Earnings - Defense World

04:05 AM

02:47 AM

HC Wainwright Has Bullish Forecast for STOK FY2025 Earnings - Defense World

02:47 AM

01:27 AM

Stoke Therapeutics (NASDAQ:STOK) and Tiziana Life Sciences (NASDAQ:TLSA) Head to Head Survey - Defense World

01:27 AM

Feb 21, 2025

Trading (STOK) With Integrated Risk Controls - Stock Traders Daily

Feb 21, 2025

Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from Chardan Capital - Defense World

Feb 21, 2025

Feb 20, 2025

Stoke Therapeutics’ Collaboration with BioGen - Global Legal Chronicle

Feb 20, 2025

Biogen and Stoke Therapeutics collaborates to develop Dravet syndrome treatment globally - MSN

Feb 20, 2025

Feb 19, 2025

Fenwick Represents Stoke Therapeutics in Strategic Collaboration with BioGen - Fenwick & West LLP

Feb 19, 2025

Biogen bags rights to epilepsy drug from Stoke in $550m deal - pharmaphorum

Feb 19, 2025

Stoke Therapeutics (NASDAQ:STOK) Shares Down 6.5% – Here’s Why - Defense World

Feb 19, 2025

Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment - Yahoo Finance

Feb 19, 2025

Stoke Therapeutics (NASDAQ:STOK) Given New $47.00 Price Target at HC Wainwright - Defense World

Feb 19, 2025

Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC - Defense World

Feb 19, 2025

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments - BioSpace

Feb 19, 2025

Feb 18, 2025

Biogen takes territorial rights to Stoke’s Dravet program: Deals Report - BioCentury

Feb 18, 2025

Stoke Gets Runway, Biogen A Late-Stage Asset In Epilepsy Collaboration - News & Insights

Feb 18, 2025

Biogen’s Bold Bet: A New Hope for Dravet Syndrome Shines Bright - Smartphone Magazine

Feb 18, 2025

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal - Yahoo Finance

Feb 18, 2025

Biogen continues dealmaking buzz with Stoke Therapeutics - The Business Journals

Feb 18, 2025

Biogen buys rights to Stoke’s rare epilepsy drug - BioPharma Dive

Feb 18, 2025

Biogen Bets Up to $550 Million for Rights to Epilepsy Drug - Bloomberg

Feb 18, 2025

BTIG maintains Stoke Therapeutics stock with $29 target By Investing.com - Investing.com UK

Feb 18, 2025

HC Wainwright Adjusts Price Target on Stoke Therapeutics to $47 From $35, Maintains Buy Rating - Marketscreener.com

Feb 18, 2025

Biogen And Stoke Therapeutics Enter Into Collaboration -February 18, 2025 at 10:00 am EST - Marketscreener.com

Feb 18, 2025

Strategic Collaboration and Positive Clinical Data Propel Stoke Therapeutics to a Buy Rating - TipRanks

Feb 18, 2025

Biogen, Stoke Partner on Dravet Syndrome Investigational Drug Zorevunersen -February 18, 2025 at 09:39 am EST - Marketscreener.com

Feb 18, 2025

Biogen partners with Stoke Therapeutics to sell severe epilepsy drug - STAT

Feb 18, 2025

Biogen and Stoke Thera ink deal on zorevunersen development - The Pharma Letter

Feb 18, 2025

Biogen and Stoke Therapeutics collaborate to develop Dravet syndrome treatment globally - Seeking Alpha

Feb 18, 2025

Biogen, Stoke partner for Dravet syndrome treatment - Investing.com

Feb 18, 2025

Biogen, Stoke partner for Dravet syndrome treatment By Investing.com - Investing.com South Africa

Feb 18, 2025

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy - MarketWatch

Feb 18, 2025

Biogen partners with Stoke Therapeutics on drug for severe epilepsy - STAT

Feb 18, 2025

Major Epilepsy Treatment Breakthrough: Biogen Acquires Rights to FDA-Designated Therapy in Massive Deal - StockTitan

Feb 18, 2025

Feb 16, 2025

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer - Seeking Alpha

Feb 16, 2025

Feb 12, 2025

Sector Update: Health Care Stocks Softer Wednesday Afternoon -February 12, 2025 at 01:47 pm EST - Marketscreener.com

Feb 12, 2025

SG Americas Securities LLC Sells 4,149 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World

Feb 12, 2025

Sector Update: Health Care Stocks Retreat Late Afternoon -February 12, 2025 at 03:54 pm EST - Marketscreener.com

Feb 12, 2025

Feb 11, 2025

Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 9.7%Here's Why - MarketBeat

Feb 11, 2025

Feb 10, 2025

Long Term Trading Analysis for (STOK) - Stock Traders Daily

Feb 10, 2025

Understanding the 7.51% Volatility Levels of Stoke Therapeutics Inc’s (STOK) Stock in the Past 30 Days - The News Heater

Feb 10, 2025

STOK’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

Feb 10, 2025

Feb 08, 2025

Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 8.2%Here's Why - MarketBeat

Feb 08, 2025

Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength? - MSN

Feb 08, 2025

Feb 07, 2025

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $21.29 Average Price Target from Analysts - Armenian Reporter

Feb 07, 2025

Feb 06, 2025